Pharmacokinetics and safety of an oral ALK inhibitor, ASP3026, observed in a phase I dose escalation trial

Category Primary study
JournalJournal of Clinical Oncology
Year 2013
This article has no abstract
Epistemonikos ID: 8b5718b791f45660bb473c9520568c4ef00c37ea
First added on: Feb 05, 2025